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Hematopoietic stem cells (HSC) sustain blood production over theentire life-span of an organism. It is of extreme importance thatthese cells maintain self-renewal and differentiation potential
over time in order to preserve homeostasis of the hematopoietic system.
Many of the intrinsic aspects of HSC are affected by the aging process
resulting in a deterioration in their potential, independently of their
microenvironment. Here we review recent findings characterizing most
of the intrinsic aspects of aged HSC, ranging from phenotypic to molec-
ular alterations. Historically, DNA damage was thought to be the main
cause of HSC aging. However, over recent years, many new findings
have defined an increasing number of biological processes that intrinsi-
cally change with age in HSC. Epigenetics and chromatin architecture,
together with autophagy, proteostasis and metabolic changes, and how
they are interconnected,  are acquiring growing importance for under-
standing the intrinsic aging of stem cells. Given the increase in popula-
tions of older subjects worldwide, and considering that aging is the pri-
mary risk factor for most diseases, understanding HSC aging becomes
particularly relevant also in the context of hematologic disorders, such as
myelodysplastic syndromes and acute myeloid leukemia. Research on
intrinsic mechanisms responsible for HSC aging is providing, and will
continue to provide, new potential molecular targets to possibly amelio-
rate or delay aging of the hematopoietic system and consequently
improve the outcome of hematologic disorders in the elderly. The niche-
dependent contributions to hematopoietic aging are discussed in another
review in this same issue of the Journal. 
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ABSTRACT
Introduction
Aging is the largest risk factor for many chronic diseases and disabilities. Not sur-
prisingly, aging is also the major risk factor for several hematologic syndromes and
malignancies, such as myelodysplastic syndromes (MDS) and acute myeloid
leukemia (AML).1 Moreover, aging has a negative impact on HSC regenerative
capacity, and for this reason, cell-intrinsic mechanisms of aging are important puta-
tive targets for therapeutic interventions in order to ameliorate the consequences of
aging on HSC and on the hematopoietic system.2 Understanding the mechanisms
of HSC aging will provide the scientific community with new tools to improve the
regenerative capacity of healthy HSC and thus the function of the hematopoietic
system in the elderly. 
The elderly population is growing rapidly worldwide. In addition, hematologic
disorders and leukemia are exponentially growing with aging, without an equiva-
lent acceptable growth in the therapeutic management of these diseases in the eld-
erly; this is in sharp contrast to the increase in successful therapies for leukemia in
younger patients. So far, with conventional induction therapy, many elderly
patients experience a very poor overall survival rate, while requiring substantial
social and medical assistance during their few remaining months of life, at a signif-
icant cost to the health service.3,4
A focussed understanding of the biology of aging in
HSC and new therapeutic approaches is, therefore,
mandatory.
Intrinsic aging drivers
Hematopoietic stem cells are the cornerstone of the
hematopoietic system. Like other adult stem cells, they
need to be localized in special niches that support and con-
trol the main stem cell functions: self-renewal and differen-
tiation. Since HSC are so critical to the hematopoietic sys-
tem and have to be functional during the entire life-span of
the organism to maintain blood homeostasis, it is logical to
think that somehow they require special protection from
aging. Several studies have been trying to address how
HSC can endure the effects of aging. However, investigat-
ing HSC function in living organisms is extremely challeng-
ing, since HSC constitute a rare cell population that, for
most of the time, remain quiescent, undergoing very few
divisions during the life-span of the organism (reviewed by
Chandel et al.5 and Singh et al.6). During aging, changes
occur both in the niche, defined as extrinsic, and within the
HSC, therefore dependent exclusively on the stem cell
itself and, by definition, transplantable. 
Working on human aging, especially in the hematopoi-
etic system, has important experimental limitations and
for this reason most of the research has been performed in
model systems, particularly mouse models. Although
some aging characteristics can be translated from mice
into the human system, some phenotypes and their mech-
anistic investigation do not find a parallel in humans.
Therefore, the development and establishment of possible
new therapies must involve research on humans, or at
least on models more similar to humans, such as non-
human primates. Throughout this review, we discuss
findings obtained in murine studies and we highlight
some results obtained from studies carried out also in non-
human primates and humans.
In general terms, a set of phenotypic and functional
alterations have been consistently reported to characterize
aged HSC (Figure 1).
Increase in phenotypic HSC number and decrease
regenerative capacity 
The number and frequency of HSC in the bone marrow
of mice and humans increase with aging, while their
regenerative capacity measured in transplantation assays
is clearly reduced. It is accepted among researchers that
this phenotype is caused primarily by cell-intrinsic mech-
anisms,7-9 even though an aged microenvironment can fur-
ther aggravate it.10-12
Myeloid skewing
Aged HSC show an increased differentiation potential
to the myeloid lineage and a decrease in the potential to
differentiate into the lymphoid lineage.9,13,14 Moreover,
even though the number of myeloid cells is higher, their
quality is compromised.15,16 Interestingly, experiments
dealing with single cell transplantations in mice17 and
scRNA-sequencing (scRNA-seq) profiling18 have shown
that HSC differentiation potential is not as homogenous
as it was thought. In particular, “myeloid-restricted repop-
ulating progenitors” (MyRP) have been characterized
within the young HSC compartment.17 This MyRP sub-
population increases dramatically with age, in contrast
with the moderate increase in the amount of multipotent
HSC.17,18 Intriguingly, within this MyRP subpopulation, a
subset of cells called “latent-HSC” can revert to the multi-
potent HSC state upon secondary transplants only in the
aged samples.17 Consequently, it would be interesting to
know if this subpopulation exists, and if it has the same
behavior and features in the human bone marrow as in
mice, in order to optimize transplantation therapies
involving aged patients. These results highlight the poten-
tial importance of single cell profiling, at the molecular and
at the cellular level, in order to better characterize also the
human HSC compartment.
DNA damage
Accumulation of DNA damage is a common feature of
aging in different tissues in many organisms, including
humans.19 Although HSC have many mechanisms that
enhance their capacity for protecting their genome from
DNA alterations,20,21 some specific mutations have been
shown to be highly recurrent in HSC.10 In addition, upon
aging, some of these somatic mutations are fixed and
expand within the aged HSC compartment and are
thought to be causally involved in the emergency of spe-
cific clones, which are the biggest contributors  to replen-
ishing the hematopoietic system.22 It is possible that some
of these mutated clones could eventually progress to
blood malignancies such as MDS or AML, although this is
not necessarily the case.23
Clonality
In a young individual, hematopoiesis is normally sup-
ported by different HSC clones with similar potential.
This has been demonstrated by limiting-dilution trans-
plantation experiments.10 However, in the elderly, even
though there is an increase in the number of HSC in the
bone marrow niche,8 there is a smaller number of HSC
clones that disproportionally contribute to the peripheral
blood production (reviewed by Akunuru and Geiger2).
This phenomenon is termed Clonal Hematopoiesis of
Indeterminate Potential (CHIP)24 and is frequently detect-
ed in individuals over 55-60 years of age, being associated
with an increased risk of hematopoietic malignancies and
enhanced cardiovascular risk.25 In recent years, there has
been increasing interest in studying how CHIP develops
over time and eventually evolves into hematopoietic
malignancies, given that this might prove useful in devel-
oping therapeutic approaches.23,26
Epigenetic drift
Specific changes occur in the epigenome and chromatin
organization of aged HSC compared to young HSC. These
changes include DNA methylation,27 specific histone post-
translational modifications, and chromatin reorga -
nization.28
Cell polarity
Several molecules appear to be polar within the cell and
the nucleus in young HSC when compared with aged
HSC. For some of these molecules, both their polarity fea-
ture and the functional relevance are conserved from
Drosophila to humans. In recent years, a few studies have
demonstrated that the impairment in the function and
stem potential of HSC upon aging are directly related to
the loss of polarity of selected biomolecules within the
cell.12,15,29,30
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Figure 1. Intrinsic hallmarks of hematopoietic stem cells (HSC) aging. (A) Representative features of young HSC. (B) Representative features of aged HSC. K16ac:
H4K16ac; met: DNA methylated; green me3: H3K4me3; red me3: H3K27me3. ROS: Reactive oxidative species; PRC2: Polycomb Repressive Complex 2.
Metabolic alterations and impaired autophagy 
Hematopoietic stem cells are characterized by having a
low metabolic rate, being essentially glycolytic while qui-
escent.5,31 Upon activation, young HSC change towards a
more oxidative metabolism that can be reverted when
they return to quiescence (reviewed by Verovskaya et al.32).
However, in aged HSC, basal metabolism is shifted to a
higher level of oxidative metabolism (reviewed by
Verovskaya et al.32), which increases reactive oxidative
species (ROS) leading to oxygen related-stress, accompa-
nied by impaired regenerative potential (reviewed by
Chandel et al.5). Metabolic stress can fire autophagy in the
cell, which is a “housekeeping" mechanism involved in
self-degrading components of the cell in response to a spe-
cific stress.33 The process consists of enclosing organelles or
portions of the cytosol within double membrane vesicles,
which later fuse with the lysosome, where the degradation
takes place.33,34 Autophagy deregulation has been related
with aging and with age-related diseases such as cancer.34,35
Altered proteostasis
Proteostasis or protein homeostasis is described as the
situation of balanced levels of protein biogenesis and
degradation.36 Proteostasis is regulated by several mecha-
nisms such as autophagy, the ubiquitination proteasome
system (UPS), the unfolded protein control system (UPR),
and the proper levels of protein translation.37 As men-
tioned above, autophagy is impaired with age, but also
UPS and UPR levels are reduced leading to a situation of
protein stress that contributes to loss of regenerative
potential of aged HSC.36,38,39
Alterations in intrinsic signaling pathways
Signaling pathways such as TGF1-β, Notch, NF-kB or
Wnt have an essential role in modulating the response of
the hematopoietic system within the hematopoietic
niche, tightly regulating the balance between quiescence
and differentiation.40-43 These pathways are intrinsically
altered in aged HSC, with a consequent effect on their
function.15,28,44,45
The hallmarks of intrinsic HSC aging cover a very
diverse group of biological characteristics that might nev-
ertheless be all interconnected. Here, we will focus on
some of these intrinsic molecular aspects, that are implied
in driving functional and phenotypical alterations of HSC
upon aging. 
Is DNA damage a driver of HSC aging?
DNA damage and genomic instability are thought to be
primary causes of mutation accumulation upon aging,
leading to cancer or premature aging of tissues.19
Here we summarize what is known about the effects of
DNA damage on aging of HSC under a different perspec-
tive, with consideration of new data generated by state-
of-the-art techniques.
From DNA damage to hematopoietic clonality
There are premature aging syndromes, such as Werner
or Bloom syndrome, in which the cause of the disease is
the accumulation of mutations due to an inefficient DNA
damage repair. The accumulated mutations in these syn-
dromes lead to different kinds of cancer to arise at early
age together with some premature aging phenotypes such
as immunosenescence, skin fragility and osteoporosis.
However, these syndromes recapitulate only some physi-
ological aging characteristics, but not all.46
In the case of HSC, work performed on mice deficient
in DNA repair proteins shows an expected reduction in
HSC repopulation potential together with a decrease in
their self-renewal capacity, driving a reduction of the
whole HSC pool.31,47,48 As one of the most evident pheno-
types occurring upon chronological aging is the expansion
of HSC, the phenotype observed in mice deficient in DNA
repair proteins sharply contrast with physiological HSC
aging. More recently, it was elegantly shown by genetic
barcoding and clonal functional evaluation of young and
aged HSC followed by induced pluripotent stem cells
(iPSC) generations and re-differentiation that, despite the
heterogeneity of the aged HSC pool, several functional
aspects of HSC aging could be reversed to a young-like
state. These data strongly support the view that accumu-
lations of DNA mutations in genes critical for
hematopoiesis would not be the principal mechanism for
the aged-dependent functional decline of HSC,49 although
they might contribute to clonality.22,23
Still, mutations occur in every tissue and they are shown
to accumulate with age. It has been calculated that somat-
ic mutations in human HPSC occur and accumulate in life
in a linear rate of 14bp base substitutions per year, which
is similar to or even lower than other tissues.50
γH2A has been historically interpreted as being a marker
of DNA damage in general, and in HSC in particular, since
it is one of the first signals occurring at the damaged site
and it is needed for subsequent DNA repair.48,51 Aged HSC
present with increased numbers of γH2A foci compared to
young HSC.48 Therefore, it was logical to conclude that
there is deficiency in DNA repair in old HSC because of
the persistence of γH2A. Interestingly, γH2A foci have
been demonstrated to be not only markers of double
strand breaks (DSB). γH2A  also signals DNA replication
stress (i.e. replication fork collapse) and it accumulates at
rDNA in old quiescent HSC. Furthermore, in aged murine
HSC, γH2A cannot be removed by the specific phos-
phatase (PP4c) as efficiently as it is removed in young HSC
because PP4c is mis-localized.21
Moreover, murine young and old HSC have been
demonstrated to be equally efficient in repairing DNA
under induced DNA damage.20,21,52 HSC make this possible
by having the main DNA repair pathways attenuated
while quiescent and reactivating them once they re-enter
the cell cycle.20 In addition, when young and old HSC are
subjected to DNA damage, they lack G1-S arrest and their
apoptosis rate increases in order to minimize the acquisi-
tion of mutations.52
In spite of the ability of HSC to avoid mutation accumu-
lation through age, a series of point mutations have been
found in humans to be predominant with age, as is the
case of mutations in the epigenetic regulators DNMT3,
TET2 and ASXL1, among others.53-56 These mutations
appear frequently in healthy older individuals and they are
also found over-represented in MDS and AML patients.23
It can be hypothesized that these mutations confer a com-
petitive advantage that leads to clonal hematopoiesis. This
is supported by some studies in the murine hematopoietic
system in which the loss of Dnmt3a or Tet2 enhances the
self-renewal potential of HSC.57 DNMT3a and TET2 are
epigenetic modifiers: DNMT3s catalyze DNA methyla-
tion (mC) and TET2 oxidizes mC to hydroximethyl-C,
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which leads to de-methylation of DNA (reviewed by
Zhang et al.58). As has been demonstrated in mouse mod-
els, TET2 seems to contribute to both differentiation and
self-renewal through gene activation and repression, and
DNMT3a might contribute to the same functions by
repressing HSC genes and generating substrates for TET2
action.58 The overall result is that both DNMT3 and TET2
co-operate to prevent activation of lineage-specific tran-
scription factors in HSC.58 As for ASXL1, it seems that by
binding to chromatin when mutated it can alter the
epigenome, increasing the tendency towards CHIP or
even leukemic transformation in mice.59 Mutations in the
human homologs of these genes have also been found to
be related to clonal hematopoiesis and MDS.60,61
However, these mutations in humans do not necessarily
involve the development of malignancy (although this
might occur), probably in combination with other
unknown events.23,62 In addition, MDS does not necessari-
ly always lead to the development of AML. The combina-
tion of different mutations might be critical to allow the
development of sub-clones with higher competitive
advantage implied in the final establishment of MDS or
AML.23
Telomere shortening is a special kind of DNA damage in
which the low activity of telomerase or its absence makes
the length of telomeres shorter after every division cycle
and leaves the DNA ends unprotected, activating the
DNA damage response and DNA repair pathways
(reviewed by Behrens et al.63). Since telomeres become
shorter every cycle, their length is intimately related to the
life-span of a cell. Based on this assumption, there have
been many attempts to understand if and how telomere
length is related to life-span of the entire organism.
Experimental observations indicate that the lower the rate
of telomere shortening, the higher the life expectancy.64,65
As for HSC, it has long been known that they can only be
serially transplanted 4-6 times in mice before they start
showing loss of multi-lineage reconstitution capacity.66
This outcome was linked to limited replicative potential
due to telomere shortening. However, it has been reported
that HSC telomere length does not decrease in serial trans-
plantation assays,67,68 and the overexpression of telomerase
in mice does not lead to prolonged HSC transplantation
capacity.67 The difference between mice and humans is
remarkable in how the hematopoiesis system is affected
by telomere attrition. For example, only the fifth genera-
tion on a Tert-/- mouse background develops anemia.69 This
might be due to the elevated tolerance of murine HSC to
accumulate alterations in their genome upon telomere
shortening, either by entering in a senescence state or by
undergoing apoptosis.70 In contrast, human patients of
telomeropathies like Dyskeratosis congenita or adults with
telomere gene mutations display very early bone marrow
failure and severe aplastic anemia,71 which make the
patients dependent on transplantation therapy.
Interestingly, a recent study with mice has shown that
the loss of expression of Pot1a, a ssDNA binding protein
part of the shelterin complex that binds telomeres, dimin-
ishes the potential of LT-HSC in vitro and in vivo, and its
overexpression increases the contribution of LT-HSC to
peripheral blood and bone marrow after secondary trans-
plant, even rescuing the myeloid skewing in aged mice.72
Importantly, Hosokawa et al. included data showing that
also the human homolog, POT1, improved ex vivo cultur-
ing of human cord blood HSC.72
Clonal hematopoiesis seems to stem out as a conse-
quence of HSC mutation accumulation during aging
(Figure 2). As has been shown in mice, the HSC compart-
ment has a clonal dynamic nature that changes over time,
with individual clones that expand or shrink, disappear or
appear.26 However, there are differences between the
results obtained in mice and those obtained in other
model organisms, such as non-human primates. An exten-
sive study dealing with the impact of aging on non-human
primate hematopoiesis was recently published. It was
demonstrated by lentiviral barcoding and high-throughput
sequencing that aged macaques show a delay in the emer-
gence of hematopoietic contribution in transplantations of
autologous HSPC compared to mice, together with a per-
sistent output from both B-cell and myeloid-biased
clones.73 These results on clonal behavior of aged non-
human primate HSC is of special importance for diagnosis
and therapy in humans, since it is unfeasible to clonal-
track HSC in healthy patients. Mainly, information on
human clonality and its progression upon aging comes
from studies of “end-point” clonal population in healthy
aged patients62 or by tracking existing clones from MDS
patients to monitor their progression to AML over time.23
Importantly, a very interesting simulation tool has been
recently reported in order to understand clonal contribu-
tion to hematopoiesis that can be applied to different
species, from mice to humans.74
Under the premise that clonality is the result of specific
mutations that give rise to “fitter” hematopoietic clones
which are more successful after the selective process, one
last question continues to be asked: does clonality result
from intrinsic changes in aged HSC, or is it rather that
clones are selected by the microenvironment?75 Still, it is
possible that the impairment of hematopoiesis upon aging
might be the result simply of fewer contributing fit HSC
which did not undergo intrinsic changes and which some-
how resist microenvironment pressure.
In order to address clonal hematopoiesis and the predis-
position to develop blood malignancies with age, many
laboratories have tried to engineer AML mouse models. It
has been shown that, for example, the deletion of Tet2, in
mice leads to deregulated hematopoiesis and subsequent
development of blood malignancies;76 however, the phe-
notype that is observed in aged human patients is not
recapitulated completely in the murine models, either
because of the onset of the disease, its penetrance, or the
malignancy of the developed disease.76,77 New molecular
biology approaches and a deeper understanding of the
HSC aging process might be critical to improve the tools
that are currently available.77
Epigenetic changes: DNA methylation, histone
marks and chromatin architecture
Genome-wide expression profiling of murine young
and aged HSC has shown that there are transcriptional
alterations associated with aging in HSC which affect
myeloid and lymphoid differentiation.7,28,43,78 Single-cell
RNA sequencing (scRNAseq) has become a powerful tool
to identify variations in transcriptional profiling between
different cells from the same compartment, as in the case
of HSC in the murine bone marrow. The information
retrieved from scRNAseq from young and aged murine
HSC has revealed that there is a molecular bias priming
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platelet genes expression at the expense of lymphopoietic
genes, confirming the well-known myeloid skewing fea-
ture of aged HSC.18,79
The suggested mechanisms underlying such a genome-
wide transcriptional change are related to the epigenomic
regulation. Indeed, there is much evidence to support this
hypothesis. For example, by reprogramming young and
aged murine hematopoietic progenitors, the repopulation
potential is indistinguishable between young and aged
derived iPS into all hematopoietic lineages in chimera indi-
viduals and in HSC transplantations.49,78 These data imply
that reprogramming is resetting the epigenetic state of the
HSC regardless of the age at which the cells are repro-
grammed. Moreover, these data also suggest that epige-
netic alterations that occur upon aging are reversible.80,81
The epigenomic landscape of HSC has been shown to
change with respect to DNA methylation, histone modifi-
cations and chromatin architecture (Figure 2).
DNA methylation changes from young to aged
hematopoietic stem cells 
Global hypomethylation occurs in most somatic cells
and in primary cells during aging.19,81 In contrast, the major-
ity of DNA methylation signatures during HSC aging in
mice are highly conserved.27,28,82 However, the overall
methylation change of aged HSC compared with young
HSC is different depending on the study. The studies per-
formed using reduce-representation bisulfite sequencing
(RRBS)27,28 showed a slight tendency to hypermethylation
with aging. In contrast Taiwo et al. reported a slight but
significant (5%) global loss of DNA methylation by Me-
DIP-seq. Taiwo et al. argue that the difference could be
explained by the difference in coverage of each technique.
Bisulfite-sequencing provides generally 5-10% genome
coverage, in contrast with 60% provided by MeDIP-seq.82
Interestingly, independently from the overall hypo- or
hypermethylation detected, all studies so far report high
similarities in the alterations at specific loci that gained or
lost methylation. One of the clearest examples involves
polycomb repressive complex (PRC2) target genes, which
are hypermethylated in aged HSC.27,82 It has been demon-
strated in a human cell line that PRC2 cannot bind to chro-
matin if the DNA is hypermethylated.83 Moreover, some
PRC2 complex subunits in aged and proliferative stressed
HSC resulted in being down-regulated as measured by
RT-qPCR27 and RNA sequencing.28 These observations
Intrinsic HSC aging
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Figure 2. The nuclear compartment in hematopoietic stem cells (HSC) during aging. The nuclear compartment undergoes several changes through aging, ranging
from changes in histone post-translational modifications and DNA methylation to alterations of epi-polarity and chromatin architecture. Although the DNA damage
repair (DDR) machinery is functional when entering in cycle from quiescence, DNA mutation and hematopoietic clonality can be detected and increase in frequency
over time. CASIN treatment of aged HSC restores epi-polarity of H4K16ac, a nuclear hallmark of young HSC. K16ac:  H4K16ac; met: DNA methylated; green me3:
H3K4me3; red me3: H3K27me3. DDR: DNA damage repair.
might suggest that the methylation machinery in old HSC
might access PRC2 target sites merely as a consequence of
the reduced levels of PCR2 itself, which normally occupies
these specific targets inducing their transcriptional down-
regulation. However, this hypothesis has yet to be
demonstrated.
A possible explanation for the limitation to a more glob-
al and prominent hypomethylation on HSC during aging
is linked to their quiescence during adult life. When
murine young or old HSC are transplanted, and are there-
fore subjected to an induced proliferative stress, global
hypomethylation occurs.27 This observation agrees with
reports for aging in human somatic cells and tissues
(reviewed by Gonzalo81 and Jones et al.84). However, even
in this case, the hypermethylation of PRC2 targets is still
detectable in mice, suggesting that aging and exhaustion
promote distinct alterations on the DNA methylation
landscape.27
It is worth noting that differentially methylated genes in
aged HSC compared to young HSC are expressed or high-
ly expressed in progenitor cells downstream in murine
hematopoietic differentiation.27 This observation suggests
that the impact of alterations in DNA methylation during
aging is not probably manifested until HSC differentiate,
and never in HSC themselves. This aspect is also demon-
strated by the work of Scadden’s team, who elegantly
showed in mice that the differences in enhancer methyla-
tion between distinct HSC clones in the same individual
has no effect on gene expression until stem cells differen-
tiate into subsequent hematopoietic sub-compartments.26
Histone post-translational modifications upon
hematopoietic stem cell aging 
A number of histone tail modifiers have been involved
in HSC function and also have a role in chromatin remod-
eling, which supports the concept that changes in the
chromatin state within the HSC compartment are impor-
tant for blood homeostasis in both mice and human sys-
tems. Among them, we can find PRC2 subunits such as
Ezh2, Suz12 and Eed,85-87 histone specific lysine-demethy-
lases such as Jarid1b/KDM5b,88 UTX/KDM6a89 or
Lsd1/KDM1a,90 or histone methyltransferases such as
SUV39H1.91
Moreover, it is known that the expression levels of
some of these proteins  change upon aging,27,28,43,91 suggest-
ing that histone modifications are different in old HSC
when compared to young HSC. 
Goodell’s group performed one of the most accurate
studies of epigenomic modifications in murine HSC upon
aging. Some of the principal regulatory histone marks were
profiled by ChIP-seq in HSCs from 4-month old and 24-
month old mice. Although the dataset revealed only mod-
erate changes, some interesting unique features were
reported. For example, regarding H3K4me3, there was
only an increment of 6.3% in peak deposition in old versus
young HSC, but most of the peaks were generally broader.
As for H3K27me3, peak counts remained similar but an
increase in the length of coverage by 29% was detected
upon HSC aging. Moreover, the intensity of the signal
increased by 50%. In relation to H3K36me3, the peaks
moved from the TSS to the transcription termination site,
and H3K36me3 and H3K27me3 behaved in a mutually
exclusive manner. A strong positive correlation between
transcriptome changes and the three histone marks ana-
lyzed in the study was also reported.28
Regarding other histone marks, H4K16ac levels and
localization have been demonstrated to change with age
in murine HSC. H4K16ac shows a prominent distribution
in one pole of the nucleus in young HSC by single cell 3-
dimensional (3D) immunofluorescence analysis. This
characteristic is defined as “epigenetic polarity” or “epipo-
larity”. Old HSC show reduced levels of H4K16ac, which
also displays apolarity and localizes evenly all over the
nucleus.14,15,29 The polarity and levels of several other his-
tone marks such as H3K4me1, H3K4me3, H4K8ac,
H3K27ac and H4K5ac showed no aged-dependent
changes in murine HSC and ST-HSC.29 Interestingly, the
loss of epipolarity and the reduction of global H4K16ac
deposition upon aging in HSC did not primarily correlate
with global changes in gene expression.15 H4K16ac was
associated to the modulation of higher-order chromatin
and protein interactions between chromatin and non-his-
tone proteins,92 and was shown to be targeted by inhibit-
ing Cdc42 activity and LaminA/C expression. H4K16ac
role in chromatin architecture in HSC will be further dis-
cussed below.
In the context of human AML, H4K16ac levels seem to
be linked to the nuclear localization of PAK4, a target of
the orphan gene C3orf54/INKA1, which promotes self-
renewal by inhibiting differentiation of cord blood HSC.93
C3orf54/INKA1 seems to be up-regulated in leukemic stem
cells in AML patients, while PAK4 is an effector of Cdc42
in humans.94
Altogether, the results obtained over the last decade sug-
gest that aging has an effect on histone mark landscape in
HSC. However, the specific alteration of histone marks
upon aging not always correlates with global change on
gene expression in HSC themselves, but it rather affects
the expression of genes in downstream progeny during
the differentiation program, as we stated above also for
the methylation profile.15,26,27 Altogether, this makes epige-
netic studies extremely cumbersome in HSC and subtle
differences within this cell population might indeed make
a functional impact visible only under specific challenges.
Chromatin architecture changes 
Over recent years, chromatin architecture has become
more important for gene expression, cell division, fate
determination, growth and development, disease and
even genome evolution (reviewed by Kong and Zhang95).
Recent studies have proposed the existence of two differ-
ent but related ways of 3D chromatin organization: the
cohesin-dependent CTCF loops and the small compart-
mental domains that are formed as a consequence of tran-
scription and chromatin state (reviewed by Rowley and
Corces96). In this regard, and in relation to HSC biology,
some disease-associated mutations in humans that affect
proteins involved in establishing or preserving chromatin
architecture have been described, for example, proteins
belonging to the cohesin complex, such as Stag2, Rad21
and Smc3, which have been associated with AML and
MDS particularly in the elderly.97,98 
Chromatin accessibility changes upon HSC aging have
just started to be investigated. Recently, we performed sin-
gle-cell ATAC-seq on HSC daughter pairs from young and
old mice. The results showed that there was a greater dif-
ference between young pairs, more “asymmetrical”, as
based on quantity of ATAC-seq peaks, than those coming
from aged pairs, which were, therefore, more “symmetri-
cal”. This observation was correlated to H4K16ac distribu-
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tion in daughter cells that was more asymmetric in young
compared to old pairs. Signature-based, daughter stem
cells were in general associated to an overall lower
amount of ATAC-seq peaks, suggesting a progressive
increase in chromatin accessibility upon differentiation.15
Interestingly, both young and aged daughter stem cells
preserved open chromatin regions linked to glycolysis and
small RhoGTPases signatures. Aging was found to impact
prominently on the specific signature of open regions
associated to critical signaling pathways in HSC (Wnt sig-
naling was associated with aged HSC, while young cells
were enriched for VEGF, TGFβ and EGF signaling). In
addition, daughter progenitors maintained signatures
linked to lipid metabolism and platelet homeostasis in
both young and aged cells, while mostly they differed
again for open regions linked to specific signaling path-
ways (interferon, IFG1 and IL2 were characterizing young
cells and TNF was enriched in aged cells).15
Specific chromatin architectural alterations affecting
broader alterations have also been detected in aged
murine HSC, such as the relative position of chromo-
somes. We have observed that chromosome 11 homolog
proximity changes upon aging specifically in HSC. This
chromosomal rearrangement is dependent on LaminA/C
expression and Cdc42 activity.29 Indeed, we demonstrat-
ed that upon aging and in chronologically young
LaminA/C knock-out HSC, chromosome 11 homolog
proximity was altered and this correlated with the func-
tional impairment of stem cells. Inhibiting Cdc42 activity
could restore LaminA/C expression and localization, and
also chromosome 11 homolog proximity. Overall, these
findings support the functional relevance of chromatin
architecture also for HSC aging and, most importantly,
show for the first time that is possible to pharmacologi-
cally target the chromatin architecture to rejuvenate aged
HSC function.29
Aging and the epigenetic drift
Epigenetic drift is the term that covers all changes that
have a general effect on the epigenome and the chromatin
architecture.99,100 Recently, an exciting report of the epige-
netic drift in murine aging across tissues has been pub-
lished. Benayoun et al. showed that the aged-related alter-
ations observed in the epigenome and transcriptome land-
scape lead to induction of inflammatory responses, mainly
interferon related, across different tissues upon aging.100 In
humans, the epigenetic drift has been studied at the sin-
gle-cell level on peripheral blood mononuclear cells from
subjects of different ages.101 In agreement with previous
studies performed on bulked murine HSC,27,28 they
observed an increment of H3K4me3 and H3K27me3 with
age. These variations were reflected in transcriptional
alterations and an association of H3K4me3 with DNA
breakage and translocation was also observed.102
The fact that the observed epigenetic drift is consistent
between mice and humans suggests that it is a conserved
phenomenon in mammals. However, its ultimate manifes-
tation seems very heterogeneous, even within cells and
tissues of the same individual. This has been demonstrat-
ed using different approaches such as the generation of a
multi-color Hue mouse model as a clonal tracking tool26
and single-cell transcriptomics to study the transcriptional
behavior of each clone.26,103 These two studies agreed in
identifying (based on transcriptome analysis) distinct
clones in aged individuals that have different regulatory
states as a consequence of the epigenetic drift occurred
upon aging.26,103
Metabolism and hematopoietic stem cell aging
Hematopoietic stem cells are quiescent during most of
their lifespan and their metabolic needs are relatively low.
However, one of the aging hallmarks is the dysregulation
of metabolic pathways, and this aspect might indeed be
critical for HSC function, too. Here we detail some of the
key metabolic aspects related to HSC aging (Figure 3).
Effects of oxidative stress and mitochondria homeosta-
sis in hematopoietic stem cell aging 
It has been shown that artificially altering mitochondrial
function can lead to acquiring aging phenotypes in HSC,
such as loss of self-renewal and lymphoid/myeloid skew-
ing. Sometimes these mitochondrial-related aging pheno-
types can be reverted by the addition of redox scavenger
compounds [N-acetylcysteine (NAC), rapamycin or
MAPK inhibitors]. Normally, rapamycin and calorie
restriction can only partially rescue the effects of aging
due to intrinsic deteriorated mitochondrial activity
(reviewed by Chandel et al.5).
Reactive oxygen species (ROS) are the natural side-
product of oxygen-based metabolism and are produced
mainly by mitochondria. The effect of ROS in aging has
been historically attributed only to the oxidation of DNA,
RNA and proteins, but it has an important role in cell sig-
naling, too. ROS can be detected by redox sensors that
ultimately fire oxidative stress response such as enzymes
and transcription factors (reviewed by Bigarella et al.104).
In HSC, high levels of ROS can generate oxidative stress
and lead to loss of quiescence in the cells; therefore, ROS
levels have to be tightly controlled (reviewed by Bigarella
et al.104). Quiescent HSC have a low metabolic rate, which
involves low levels of reactive oxygen species (ROS).105 It
has been shown in mice that the frequency of HSC with
low levels of ROS decreases with age, suggesting that
ROS generation/accumulation is a distinctive characteris-
tic of aging.106 Increments of ROS levels in adult HSC have
consequences that are somewhat similar to the aging phe-
notype such as myeloid lineage skewing and defective
long-term repopulation activity, as has been demonstrated
in the case of FoxO transcription factors depletion in
mice.107,108 It is very interesting that high levels of ROS in
the FoxO depleted HSC can be rescued by the addition of
the antioxidant NAC,108 but only for some weeks.107 The
importance of FoxO3 in LT-HSC function goes beyond
regulation of ROS levels since it is essential for activation
of the autophagy gene program.109
Reactive oxygen species are also augmented in HSC of
aged SIRT3 knockout (KO) mice, negatively affecting their
function, but not in young SIRT3 KO mice. Intriguingly,
overexpression of SIRT3 rescues functional aged-related
defects in HSC. SIRT3 is a deacetylase that regulates mito-
chondrial protein acetylation in mammalian cells and it is
enriched in young compared to aged HSC. Therefore, the
role of SIRT3 in the maintenance of proper ROS levels in
HSC is essential during aging.110
Mitochondrial homeostasis refers to the correct regula-
tion of the mitochondria function within the cell. Studies
using “mutator mice” (proof reading mutant for PolγA, the
catalytic subunit of mtDNA polymerase that is encoded in
the nuclear genome) showed phenotypes indicative of
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premature aging,111 including features of MDS.112
Trifunovic et al. concluded that there might be a causative
link between mtDNA mutations in these mice and the
aging phenotype.111 However, deep insights in the pheno-
type and molecular signatures of aged HSC demonstrated
that they are different from this ‘mutator’ strain, conclud-
ing that aging is primarily independent of the accumula-
tion of mitochondrial mutations.105 What is, indeed,
observed is that aged HSC show deregulation that deteri-
orates mitochondrial activity (reviewed by Oh et al.113). 
Maintenance of mitochondrial homeostasis within the
cell is also dependent on the regulation of nuclear mito-
chondrial gene expression. For example, Mohrin et al.
showed that SIRT7, a histone deacetylase, is normally
located at the proximal promoters of ribosomal proteins
and mitochondrial transcription factors within the nuclear
genome. It also binds directly to NRF1, the master tran-
scription factor of mitochondria. Eventually, SIRT7 leads
to the inhibition of the expression of mitochondrial pro-
teins in young HSC.114 Aged HSC have lower levels of
SIRT7, thus allowing an increment in the expression of
mitochondrial proteins. This, in turn, activates the PFSmt
(mitochondrial protein folding stress), a metabolic check-
point that reduces HSC quiescence. Therefore, overex-
pression of SIRT7 in aged murine HSC was shown to
decrease the levels of mitochondrial protein expression
associated with mitochondrial stress and to improve aged
HSC function.114
Autophagy
Autophagy is a major regulator of mitochondria home-
ostasis and a suppressor of the metabolism. It is regulated
by nutrient-sensing pathways like mTOR or AMPK,
which inhibit and activate autophagy, respectively. In gen-
eral, autophagy decreases with aging, due to either the
downregulation or the upregulation of critical autophagy
proteins. In HSC, the age-related decrease in autophagy
has been associated with lower capacity of glucose intake;
mitochondrial autophagy would be attenuated in order to
maintain necessary energy levels in old HSC and is rapidly
induced by FoxO3 transcription factor when HSC are
under metabolic stress.109
Genetic tools were instrumental in revealing the critical
role of autophagy upon HSC aging.115 For example, in
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Figure 3. Metabolic homeostasis and proteostasis during aging in hematopoietic stem cells (HSC). Young HSC fine-tune several biological processes: they maintain
a low metabolic rate, control protein degradation and regulate autophagy. Aged HSC show an unbalanced scenario where these processes  lose their metabolic home-
ostasis and proteostasis, converging into a status of metabolic and protein stress. Fasting is able to restore at least partially the activity of the UPRER and proteostasis
in aged HSC. ROS: reactive oxygen species; UPR: unfolded protein response.
Atg1scKO mice, autophagy is deregulated and aged HSC
present with reduced quiescence, an increased rate of dif-
ferentiation biased toward the myeloid lineage, and an
increment in OXPHOS rates. In HSC from conditional
knockout Atg12 mice, changes in the methylome of essen-
tial genes for the formation of autophagosomes have been
reported. These changes could be explained by the alter-
ations of metabolite levels caused by the loss of
autophagy, such as reduction of S-adenylmethionine
(SAM), methyl-donor co-substrate for methylases, and an
increment in alpha-ketoglutrate (αKG), a co-factor for
demethylases.35,116
Intriguingly, it was also reported that a fraction of aged
HSC showing high levels of autophagy displayed higher
resistance to exhaustion, as demonstrated by secondary
transplants in mice. These data suggest that, although
aged HSC are apparently phenotypically equal, there
might be a subset that maintains the autophagy levels of
young HSC and are consequently resilient to aging, pre-
serving their stemness and regenerative potential.35
Nowadays, autophagy represents a target for therapeu-
tic interventions in vitro and in vivo, with clinical trials
ongoing for several aged-related hematopoietic disorders,
such as AML.117,118 A number of these autophagy-targeting
approaches are based on the use of different mTOR path-
way inhibitors119 and could offer a potential therapeutic
approach to improve healthy aging as well. 
Proteostasis role in hematopoietic stem 
cell aging 
Homeostasis of proteins, also called proteostasis, indi-
cates a situation in which the proteome within the cell
reaches an equilibrium by balancing the elimination of
misfolded or damaged proteins while preserving at the
same time the necessary levels of properly assembled
proteins.36
Proteostasis relys in part on protein translation, that is,
it is directly dependent on ribosomal levels and biogene-
sis. Transcription of rRNA genes is regulated by the
methylation state of the rRNA genes themselves.
Interestingly, it has been shown that ribosomal biogene-
sis is a target of aging with hypo-methylation of rRNA
genes and higher levels of transcription in aged HSC.28
Cell polarity and aging
Cell polarity is a universal biological feature, and age
seems to be a factor contributing to the loss of cell polar-
ity regulation.120 Polarity can be defined as the asymmet-
ric distribution of cellular components, biomolecules and
structures within the cells. The number of genes linking
polarity and aging is strikingly increasing and, conse-
quently, the number of targets to be investigated in order
to ameliorate aging is growing.121 For instance, in the
baker yeast S. cerevisiae, it has been demonstrated that
damaged and aggregated proteins are retained in the
mother cell establishing an asymmetry that marks which
of the cells is  aged. The lysine deacetylase Sir2p is
responsible for this, since it regulates the ultimate correct
folding of actin in order to keep the protein aggregates in
the mother (aged) cell.122 This mechanism is highly con-
served among organisms, as is shown in Drosophila larval
and adult stem cells (female germline and intestinal stem
cells). Here, proteostasis seems to be, at least in part, reg-
ulated by asymmetric division: the shortest life-span
daughter inherits the majority of damaged proteins leav-
ing the stem cell daughter as damage-free as possible.123
This is particularly important in adult stem cells, since the
accumulation of damaged or misfolded proteins can con-
tribute to aging.36,124 Asymmetry has been described in
HSCs for several proteins such as Cdc42, Dlg, Crumb3,
Scribble, H4K16ac, LaminA/C. Polarity of these proteins
is characteristic of young HSC and apolarity is more
prominent in aged stem cells.14,15,29,44,125 CD71, the transfer-
rin receptor, and CD53 and CD63, endosomal-associated
proteins are also described to be polar and confer asym-
metry during division of HSC, being characteristic of the
most primitive population of HSC when they are togeth-
er with the stem marker CD133.126
In summary, despite the wide experimental evidence
linking loss of cell polarity and the proteostasis decay
upon aging, only a few pharmacological approaches have
been proposed so far. For example, CASIN was success-
fully used to recover HSC cell polarity and rejuvenate
function of aged stem cells in mice.14
Protein degradation systems and folding stress
response
The ubiquitin proteasome system (UPS) is a complex of
factors responsible for tagging proteins for signaling or for
degradation, and is, therefore, implied in regulating pro-
teostasis in eukaryotic cells.39 It has been shown that HSC
function can be affected by the absence or malfunction of
different UPS system factors, such as E3 ligases or deubiq-
uitinases. This happens in an indirect way, affecting the
accumulation of its protein targets, like STAT5, c-myc or
Notch, and promoting exacerbated responses.39
Moreover, the UPS regulates the degradation of histone
modifying enzymes such as HDAC1 and DNMT1.127 This
means that the epigenetic changes observed might be a
consequence of the proteasome decay occurring with
aging.128
Another system controlling proteostasis is the unfolded
protein response that occurs in the endoplasmic reticulum
(UPRER). This system preferentially induces apoptosis
under ER (endoplasmic reticulum) stress in HSPC com-
pared to closely related progenitors. The biological rele-
vance of this mechanism relys on the elimination by
apoptosis of those HSC that are under ER stress due to
accumulation of misfolded proteins.129 Intimately related
with the UPRER, protein chaperones function by enhanc-
ing the correct folding of proteins, and, in turn, protecting
against UPR-induced apoptosis. For example, the overex-
pression of the UPRER factor ATF4 and the co-chaperone
ERFJ4 in HSC isolated from human cord blood samples
confers greater repopulation capacity compared to non-
modified HSC or progenitor cells.129 
UPRER is up-regulated in intestinal stem cells (ISC) in
Drosophila with aging and oxidative stress, which leads to
age-related dysplasia and proliferation,130 although in
other biological organisms, such as C. elegans, it promotes
longevity.131 In mice, UPRER is transiently hyper-activated
after fasting-re-feeding periods as has been observed by
the overexpression of Xbp1, a transcription factor that
activates the expression of the UPRER components.
Furthermore, Xbp1 overexpression leads to hypo-
glycemia due to an improvement in insulin sensitivity
and triggers lipolysis in the liver.132 Adaptation to fasting
is linked to the UPRER system through IRE1α, a protein
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located in the ER that splices Xbp1 mRNA to a form that
activates UPRER.133 Prolonged fasting has a direct effect on
the UPRER system that influences the self-renewal and dif-
ferentiation potential of stem cells.134 However, the effects
of fasting in HSC have so far only been investigated from
a different perspective. Prolonged fasting in mice protects
HSC and progenitors within the bone marrow after
chemotoxicity and promotes balanced hematopoietic
regeneration, also in the absence of chemotherapy treat-
ment. The effect of prolonged fasting on HSC is mediated
by the low levels of expression of IGF1 (insulin-like
growth factor 1) and PKAα in starved mice.135
Signaling pathways influencing intrinsic
hematopoietic stem cell aging
Hematopoietic stem cells are located in a very special
microenvironment: the bone marrow niche.
Communication between the HSC and niche cells is essen-
tial for a correct functioning of the whole hematopoietic
system.136 Hence, it is very important that the signaling
pathways between HSC and the niche are functioning cor-
rectly throughout the life-span of the organisms. Since we
are dealing here with intrinsic alterations of HSC upon
aging, we will focus on some examples of signaling factors
and pathways within stem cells that are particularly com-
pelling in the context of intrinsic aging.
Tgf-β related
Transcriptome data analysis showed reduced TGF-β
signaling upon aging in HSC.15,28 Sun et al. calculated that
TGF-β-regulated genes were five times more likely to be
down-regulated compared to all other genes affected by
age.28 Among the TGF-β downstream genes down-regu-
lated in the study, more than half (63%) are related to bio-
logical functions that somehow sustain
hematopoiesis.43,137 In agreement with these findings,
scATACseq experiments comparing young and old HSC
have shown that TGF-β signaling is specifically enriched
in young HSC, meaning that they are in a more accessible
chromatin context, and consequently, more likely to be
expressed in young when compared to old cells.15 TGF1-
β signaling is also modulated by the regulation of the sta-
bility of its receptor upon aging. Tif1-γ (transcription
intermediary factor 1γ) regulates TGF1-βR turn over via
its ubiquitin ligase activity. Tif1-γ was reported to be
down-regulated in aged HSC, while knock out of Tif1-γ
promoted premature HSC aging. Consequently, the
amount of TGF1-βR is higher in aged HSC, making the
cells more sensitive to TGF1-β.45
Wnt related
Wnt signaling has been described to have an important
role in aging in different stem cell systems such as muscle
stem cells, adult neural stem cells or skin stem cells.138-140
In the case of muscle stem cells, with age, canonical Wnt
signaling is activated, leading to impaired muscle regener-
ation and augmented fibrosis.139 For adult neural stem
cells, it has been shown that aging leads to the overex-
pression of the Wnt antagonist Dickkopf-1 in order to
reduce neurogenesis. When Dickkopf-1 is conditionally
ablated, neurogenesis increases.138 Regarding skin stem
cells, the Wnt antagonist Klotho protects against aging by
blocking Wnt signaling.140 Wnt family members also have
a role in bone marrow function, since different members
are expressed in hematopoietic cells and in non-
hematopoietic stromal cells.141 It has been shown that
Wnt signaling is involved in the maintenance of the bal-
ance between quiescence and activation of HSC in the
bone marrow.40,142 In murine HSC, it has been shown that
there is an intrinsic increased expression of Wnt5a, shift-
ing the signaling from canonical to non-canonical in aged
HSC.44 The non-canonical Wnt pathway resulted in
Cdc42 activation and induced aging-like phenotypes
when Wnt5a was added to young LT-HSC, including apo-
larity and loss of epigenetic asymmetry at division.15,44 In
contrast, the haploinsufficiency of Wnt5 showed attenu-
ation of aging phenotypes in old HSC Wnt5a+/- mice.44
However, Wnt signaling in aging also has an extrinsic role
in the bone marrow since haploinsufficient Wnt5a+/-
recipient mice regenerate dysfunctional HSC upon sec-
ondary transplantation.143 This apparent incongruence
suggests that Wnt5a might exert both an autocrine and a
paracrine effect on HSC.
Notch related
It is known that Notch is important for the mainte-
nance of murine muscle stem cells since loss of Notch sig-
naling pathway causes impairment in regeneration of
muscle.144 In fact, the loss of satellite cells that occurs in
aged mdx mice, a murine model for the Duchenne-
Muscular-Disthropy that involves the downregulation of
the Notch signaling pathway, can be ameliorated when
Notch signaling pathway is restored.145 Recently, it was
also demonstrated in murine muscle stem cells that lig-
ands of Notch activate p53 during normal regeneration,
while this axis is impaired in aged mice leading to cell
death due to mitotic catastrophe.146
There is also evidence of the implication of Notch2,
and not Notch1 in the specific Ventricular-subVentricular
Zone (V-SVZ) adult neural stem cells, where it represses
cell cycle preserving quiescence.147
In the case of the hematopoietic system, there are con-
flicting results from different studies making this a subject
of intense debate (reviewed by Lampreia42 and Weber and
Calvi148). On one hand, the function of Notch signaling in
murine HSC has been reported several times as favoring
HSC self-renewal and expansion by in vitro stimulation of
the Notch pathway, such as the transduction of the active
intracellular portion of Notch1 or its targets, Hes1149,150 and
in vivo by the deletion of a E3 ubiquitin ligase that nega-
tively regulates Notch receptor degradation.151 However,
most studies based on in vivo loss-of-function models
seem to argue against these results, since Notch signaling
pathway is not essential for adult hematopoiesis in
mice.152,153 Notch involvement in human HSC function is
also controversial.42 On one side, inhibition of Notch by
transducing human HSCs with dnMAML1 leads to block-
age of maintenance/expansion and T-cell development in
vitro, while in vivo engraftment seems not to be affected.154
However, by using γ-secretase inhibitor (DAPT) to inhibit
Notch signaling, it has been shown that Notch pathway
is important for the repopulation capacity of human
HSC.155 
NF-kΒ related
Constitutive NF-kB activation has been involved in
aging in several murine tissues, including bone marrow,156
and in age-related myeloid malignancies like AML
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(reviewed by Zhou et al.157). A very interesting integrative
study combining human and mice datasets from young
and aged fibroblasts has revealed that NF-kB enforces the
aging phenotype and it can be targeted, at least in mice,
to revert the aged phenotype.158 Also, NF-kB signaling
seems to be activated in aged tissues and it negatively reg-
ulates autophagy (reviewed by Salminen et al.159).
More recently, NF-kB signaling activation in the
hematopoietic system has been studied under inflamma-
tion stimuli in mice showing that aged LT-HSC present
with an altered myeloid-biased response to inflamma-
tion.18
In another study, carried out in mice, aged HSC were
shown to be failing in down-regulating NF-kB signaling
when an acute inflammatory stimulus occurs,43,160 and that
this is dependent on the levels of Rad21/cohesin.160 
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Table 1. Details of documented connections between different biological processes involved in intrinsic hematopoietic stem cell aging.
Connection              Process                                                                                                                                                                           Reference
        1                            -Change in some metabolite levels affect to the activity of methylases on DNA methylation                                                             (35)
        2                            -SIRT7 overexpression in aged HSC, preserves against mitochondrial stress                                                                                      (114)
        3                            -Specific mutations in epigenetic regulators such as DNMT3, TET2 or ASXL2 tend to appear upon ageing                                (53-56)
        4                            -Accumulation of ROS is related to augmented DNA damage                                                                                                                    (107)
        5                            -Pot1 has a dual role inhibiting ATR-dependent DNA damage repair at telomeres at the same time that it controls                  (72)
                                      the expression of genes involved in ROS reduction and mTOR signaling
        6                            -Wnt non-canonical pathway activates Cdc42 in young HSC inducing ageing-like phenotypes                                                          (12,44)
        7                            -The UPS malfunctions in aged HSC which inhibits the correct degradation of histone modifying enzymes                            (127,128)
                                      such as HDAC1 and DNMT1
        8                            -rRNA genes are hypomethylated in aged HSC which involves increased rRNA transcription, more ribosomal                           (28)
                                     biogenesis and higher levels of protein translation
        9                            -TGF-β signaling-related genes are enriched in young HSC by ATAC-seq and Wnt signaling-related genes are                         (15,28)
                                      enriched in old HSC by ATAC-seq
       10                           -The UPS malfunctions in aged HSC which inhibits the correct degradation of Notch signaling-related factors                       (39,45)
HSC: hematopoietic stem cell; ROS: reactive oxygen species; UPS: ubiquitin proteasome system.
Figure 4. Interconnections between dif-
ferent biological processes involved in
intrinsic hematopoietic stem cell (HSC)
aging. We have defined five biological
processes affected during aging that
cannot be compartmentalized from
each other. They are interconnected
and a change in one of the processes
might affect the others, and all of them
converge in the final outcome of intrin-
sic aging. Specific documented inter-
connections between different biologi-
cal processes involved in intrinsic HSC
aging are numbered (1 to 10). 
Perspectives for rejuvenation and therapeutic
strategies 
In this review, we have summarized some of the most
recent and relevant information about the intrinsic fac-
tors that affect HSC upon aging. In general, we can iden-
tify at least five biological processes, which we would
define as intrinsic HSC aging mechanisms (Table 1 and
Figure 4). DNA damage, metabolism, epigenetics/chro-
matin architecture, proteostasis, and signaling. However,
the cell cannot compartmentalize hermetically each one
of these processes. This is the reason why the intercon-
nections between these biological processes will be a key
aspect in deciphering the extent of the impact of aging
on HSC. For instance, the levels of several metabolites
like SAM or ketoglutharate affect the activity of methy-
lases, which in turn have an effect on the epigenetics of
the cell.35 Investigating and understanding cellular and
molecular mechanisms of HSC aging will increase the
possibility of defining new pharmacological targets to
reduce the negative effects of aging and promote
“healthy aging”.
We are aware that most aging mechanisms that we have
reviewed here have been studied in the murine or in non-
human systems. Nevertheless, we would like to empha-
size the progress achieved so far and the importance of
pursuing an integrative research approach, to connect all
the aspects affecting stem cell aging. A broader view of
this process might indeed be central in bridging the  gap to
translation in the human system. 
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